Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial... oleh Stefanie de Groot, Hanno Pijl, Ayoub Charehbili, Saskia van de Ven, Vincent T. H. B. M. Smit, Elma Meershoek-Klein Kranenbarg, Joan B. Heijns, Laurence J. C. van Warmerdam, Lonneke W. Kessels, M. Wouter Dercksen, Manon J. A. E. Pepels, Hanneke W. M. van Laarhoven, Birgit E. P. J. Vriens, Hein Putter, Marta Fiocco, Gerrit-Jan Liefers, Jacobus J. M. van der Hoeven, Johan W. R. Nortier, Judith R. Kroep, on behalf of the Dutch Breast Cancer Research Group